share
shares
shed
suspension
suspended
suspected
sales
said
sclerosis
stock
stockbrokers
statement
system
since
set
hit
have
had
has
hunter
by
biogen
biggest
both
boost
become
better
believed
been
brought
bankruptcy
but
ms
monday
most
multiple
multifocal
mark
drug
death
deal
determine
disease
dosing
down
dublin
in
involved
investigators
increased
increasing
inquiry
into
idec
idec's
ireland-based
irish
it
its
itself
ian
elan
elan's
exchange
existing
experts
experimental
expected
either
evaluate
evaluations
end
and
analysts
as
after
action
accounts
avonex
availability
alone
also
almost
alzheimer's
approved
at
agreement
plunged
patient's
patients
partner
progressive
product
provide
prompting
price
pml
possible
pharmaceutical
phytopharm
pence
pull
on
once
of
or
out
outcome
opportunity
over
the
they
these
there's
tysabri
tysabri-treated
to
took
taking
tipped
treatment
trials
two
firm
firms
finished
from
for
four-fold
future
faced
fell
new
nervous
no
november
now
us
use
used
understand
uk
york
year
yamanouchi
lost
london
leukoencephalopathy
leading
level
last
likely
licensing
70%
while
which
was
widely
will
with
world's
work
would
43%
central
case
cases
cash
condition
consult
companies
company
competition
commercial
cited
clinical
close
closed
reports
re-initiation
receive
rebuilding
reserves
rare
raise
risk
rivals
-
growth
group
goodbody
2002
value
question
questions
$1890
$8
$2863
$3865
1984%
1515
japan's